Friday, 16 October 2026European Markets

TF1 Stock Was 9.1% Up Before The Weekend

Loading stream...

(vianews) - the market ended the session with tf1 (tfi.pa) jumping 9.1% to €7.20 on friday while cac 40 rose 0.15% to €7,476.47.

tf1's last close was €6.59, 24.34% below its 52-week high of €8.71.

about tf1

tf1 sa engages in the broadcasting, studios and entertainment, and digital businesses in france and internationally. the company offers dtt channels, including tmc, tfx, and tf1 séries films; theme channels, such as tv breizh, ushuaïa tv, and histoire tv; e-tf1; websites; and advertising services, as well as tf1, which covers sports, french drama, news, entertainment, sports, and movies. it also operates studios, including newen studios; tf1 studio; and entertainment channel comprising tf1 entertainment. in addition, the company operates unify, a digital channel. further, it offers digital content management, theme channel, content/broadcasting internet and tv, and tv news images agency services, as well as engages in the acquisition/sale of audiovisual rights and e-commerce activities. tf1 sa was incorporated in 1982 and is headquartered in boulogne-billancourt, france.

earnings per share

as for profitability, tf1 has a trailing twelve months eps of €0.8.

pe ratio

tf1 has a trailing twelve months price to earnings ratio of 8.99. meaning, the purchaser of the share is investing €8.99 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.57%.

yearly top and bottom value

tf1's stock is valued at €7.20 at 22:30 est, way below its 52-week high of €8.71 and way above its 52-week low of €5.56.

revenue growth

year-on-year quarterly revenue growth declined by 14.5%, now sitting on 2.43b for the twelve trailing months.

moving average

tf1's value is higher than its 50-day moving average of €6.56 and above its 200-day moving average of €7.09.

more news about tf1 (tfi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com